{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:00:39Z","timestamp":1788872439232,"version":"build-2803163510"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Data from head-to-head clinical trials of phosphodiesterase type 5 (PDE5) inhibitors are scarce, making it difficult for clinicians to differentiate among these agents to select the most appropriate treatment for their patients with erectile dysfunction (ED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This randomized, double-blind, crossover head-to-head clinical trial compared patient preference, efficacy, and safety of vardenafil and sildenafil in men with ED and diabetes, hypertension, and\/or hyperlipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective analysis was performed on two studies in which 1,057 men were randomized to vardenafil 20 mg (N = 530) or sildenafil 100 mg (2 \u00d7 50 mg encapsulated tablets) (N = 527) for 4 weeks. Following a 1-week washout, patients switched treatment for 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Patients were asked about overall preference: \u201cOverall, which medication do you prefer?\u201d, plus 11 other preference questions relating to their ED treatment. Efficacy assessments after each treatment period included the erectile function (EF) domain score of the International Index of Erectile Function (IIEF); Sexual Encounter Profile (SEP) diary questions SEP2 and SEP3; Global Assessment Question (GAQ); and Treatment Satisfaction Scale (TSS). Data regarding adverse events were collected throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 931 men (mean age 57.9 years) were included in the intent-to-treat (ITT) population. Non-inferiority of vardenafil over sildenafil was achieved for overall preference (vardenafil 38.9%; sildenafil 34.5%; and no preference 26.6%). Additionally, the change from baseline in the EF domain score of the IIEF achieved nominal significance for vardenafil over sildenafil (10.00 vs. 9.40; P = 0.0052). Patients also had a higher percentage of positive responses for vardenafil for SEP2, SEP3, GAQ, and 12 of 19 questions on the TSS. Both drugs were well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This randomized, double-blind, head-to-head trial in ED patients with cardiovascular risk factors demonstrated noninferiority of vardenafil for overall preference. Vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures. Both drugs were well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2006.00310.x","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T05:30:47Z","timestamp":1158643847000},"page":"1037-1049","source":"Crossref","is-referenced-by-count":51,"title":["Comparing Vardenafil and Sildenafil in the Treatment of Men with Erectile Dysfunction and Risk Factors for Cardiovascular Disease: A Randomized, Double-Blind, Pooled Crossover Study"],"prefix":"10.1093","volume":"3","author":[{"given":"Eusebio","family":"Rubio-Aurioles","sequence":"first","affiliation":[{"name":"Asociacion Mexicana para la Salud Sexual AC , Tlalpan , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Porst","sequence":"additional","affiliation":[{"name":"Private Urological Practice , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Eardley","sequence":"additional","affiliation":[{"name":"Pyra Department of Urology St James University Hospital , Leeds , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Goldstein","sequence":"additional","affiliation":[{"name":", Milton, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,11,1]]},"reference":[{"key":"2024032600181330200_bib1","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2165\/00003495-200565160-00001","article-title":"Treatment for erectile dysfunction based on patient-reported outcomes: To every man the PDE5 inhibitor that he finds superior","volume":"65","author":"Hedelin","year":"2005","journal-title":"Drugs"},{"key":"2024032600181330200_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1345\/aph.1E487","article-title":"Phosphodiesterase 5 inhibitors for erectile dysfunction","volume":"39","author":"Setter","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2024032600181330200_bib3","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2165\/00003495-200565120-00003","article-title":"A comparative review of the options for treatment of erectile dysfunction: Which treatment for which patient?","volume":"65","author":"Hatzimouratidis","year":"2005","journal-title":"Drugs"},{"key":"2024032600181330200_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eururo.2005.09.001","article-title":"Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction","volume":"49","author":"Mulhall","year":"2006","journal-title":"Eur Urol"},{"key":"2024032600181330200_bib5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1743-6109.2005.00068.x","article-title":"The efficacy of tadalafil in clinical populations","volume":"2","author":"Lewis","year":"2005","journal-title":"J Sex Med"},{"key":"2024032600181330200_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0090-4295(02)01687-4","article-title":"The efficacy of sildenafil citrate (Viagra\u00ae) in clinical populations: An update","volume":"60","author":"Carson","year":"2002","journal-title":"Urology"},{"key":"2024032600181330200_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"key":"2024032600181330200_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0090-4295(03)00491-6","article-title":"Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups","volume":"62","author":"Porst","year":"2003","journal-title":"Urology"},{"issue":"suppl 1","key":"2024032600181330200_bib9","first-page":"A16","article-title":"Vardenafil (Levitra\u00ae) improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with diabetes and erectile dysfunction","volume":"52","author":"Young","year":"2003","journal-title":"Diabetes"},{"key":"2024032600181330200_bib10","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/diacare.25.12.2159","article-title":"Effects of tadalafil on erectile dysfunction in men with diabetes","volume":"25","author":"Saenz De Tejada","year":"2002","journal-title":"Diabetes Care"},{"key":"2024032600181330200_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.281.5.421","article-title":"Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group","volume":"281","author":"Rendell","year":"1999","journal-title":"JAMA"},{"key":"2024032600181330200_bib12","doi-asserted-by":"crossref","first-page":"29C","DOI":"10.1016\/S0002-9149(99)00045-4","article-title":"Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease","volume":"83","author":"Conti","year":"1999","journal-title":"Am J Cardiol"},{"issue":"suppl 1","key":"2024032600181330200_bib13","first-page":"34","article-title":"PDE5 inhibitors: Are there differences?","volume":"13","author":"Carson","year":"2006","journal-title":"Can J Urol"},{"key":"2024032600181330200_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1743-6109.2004.10113.x","article-title":"Standards for clinical trials in male sexual dysfunction: Erectile dysfunction and rapid ejaculation","volume":"1","author":"Hirsch","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600181330200_bib15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<891::AID-SIM780>3.0.CO;2-B","article-title":"Equivalence test and confidence interval for the difference in proportions for the paired-sample design","volume":"17","author":"Tango","year":"1998","journal-title":"Stat Med"},{"key":"2024032600181330200_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1192\/bjp.178.4.325","article-title":"Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction","volume":"178","author":"Eardley","year":"2001","journal-title":"Br J Psychiatry"},{"key":"2024032600181330200_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1464-410x.2001.00998.x","article-title":"A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction","volume":"87","author":"Meuleman","year":"2001","journal-title":"BJU Int"},{"key":"2024032600181330200_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1742-1241.2000.tb10928.x","article-title":"Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology","volume":"54","author":"Olsson","year":"2000","journal-title":"Int J Clin Pract"},{"key":"2024032600181330200_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1743-6109.2005.20111.x","article-title":"Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction","volume":"2","author":"Hatzichristou","year":"2005","journal-title":"J Sex Med"},{"key":"2024032600181330200_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2004.03.011","article-title":"Efficacy of vardenafil in men with erectile dysfunction: A flexible-dose community practice study","volume":"46","author":"Potempa","year":"2004","journal-title":"Eur Urol"},{"key":"2024032600181330200_bib21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.eururo.2004.01.014","article-title":"The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men","volume":"45","author":"Hatzichristou","year":"2004","journal-title":"Eur Urol"},{"key":"2024032600181330200_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1743-6109.04043.x","article-title":"Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification","volume":"1","author":"Donatucci","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600181330200_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1743-6109.2004.04027.x","article-title":"Vardenafil improves patient satisfaction with erection hardness, orgasmic function, and overall sexual experience, while improving quality of life in men with erectile dysfunction","volume":"1","author":"Donatucci","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600181330200_bib24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1743-6109.2005.00138.x","article-title":"Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: A 12-week open-label, multicenter trial","volume":"2","author":"Mirone","year":"2005","journal-title":"J Sex Med"},{"key":"2024032600181330200_bib25","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1743-6109.2005.00150.x","article-title":"Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives","volume":"2","author":"Van Ahlen","year":"2005","journal-title":"J Sex Med"},{"issue":"suppl 3","key":"2024032600181330200_bib26","first-page":"408","article-title":"The three PDE-5 inhibitors sildenafil, tadalafil, and vardenafil\u2014Results of a comparative preference trial in 222 patients with erectile dysfunction","volume":"2","author":"Porst","year":"2004","journal-title":"Eur Urol"},{"issue":"suppl 1","key":"2024032600181330200_bib27","first-page":"41","article-title":"Patient preference in clinical practice in treatment of erectile dysfunction with PDE-5 inhibitors","volume":"1","author":"Stroberg","year":"2004","journal-title":"J Sex Med"},{"issue":"suppl 1","key":"2024032600181330200_bib28","first-page":"55","article-title":"Efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil: Results of an open label study of patient preference in Korea","volume":"1","author":"Park","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600181330200_bib29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0022-5347(18)38429-5","article-title":"Which PDE-5 inhibitor do patients prefer? A comparative randomized placebo-controlled multicenter study","volume":"171","author":"Sommer","year":"2004","journal-title":"J Urol"},{"issue":"suppl 1","key":"2024032600181330200_bib30","first-page":"21","article-title":"The use of sildenafil, tadalafil, and vardenafil in clinical practice","volume":"2","author":"Claes","year":"2005","journal-title":"J Sex Med"},{"key":"2024032600181330200_bib31","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1464-410X.2005.05892.x","article-title":"An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy","volume":"96","author":"Eardley","year":"2005","journal-title":"BJU Int"},{"key":"2024032600181330200_bib32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1368-5031.2004.00128.x","article-title":"Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction","volume":"58","author":"Stief","year":"2004","journal-title":"Int J Clin Pract"},{"key":"2024032600181330200_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1023\/A:1017554300171","article-title":"The efficacy of sildenafil in different etiologies of erectile dysfunction","volume":"32","author":"Basar","year":"2001","journal-title":"Int Urol Nephrol"},{"key":"2024032600181330200_bib34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0090-4295(02)01688-6","article-title":"Achieving treatment optimization with sildenafil citrate (Viagra\u00ae) in patients with erectile dysfunction","volume":"60","author":"McCullough","year":"2002","journal-title":"Urology"},{"key":"2024032600181330200_bib35","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1046\/j.0306-5251.2001.00027.x","article-title":"Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality","volume":"53","author":"Nichols","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"2024032600181330200_bib36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/0091270002250604","article-title":"Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction","volume":"43","author":"Rajagopalan","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"2024032600181330200_bib37","doi-asserted-by":"crossref","first-page":"I14","DOI":"10.1002\/clc.4960271305","article-title":"Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles","volume":"27","author":"Seftel","year":"2004","journal-title":"Clin Cardiol"},{"key":"2024032600181330200_bib38","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0149-2918(03)80328-4","article-title":"A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction","volume":"25","author":"Govier","year":"2003","journal-title":"Clin Ther"},{"key":"2024032600181330200_bib39","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/S0149-2918(03)80329-6","article-title":"Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: Results of a European multicenter, open-label study of patient preference","volume":"25","author":"Stroberg","year":"2003","journal-title":"Clin Ther"},{"key":"2024032600181330200_bib40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.eururo.2003.11.030","article-title":"A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil","volume":"45","author":"Von Keitz","year":"2004","journal-title":"Eur Urol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515314284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515314284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/3\/6\/1037\/47738089\/jsm_3_6_1037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/3\/6\/1037\/47738089\/jsm_3_6_1037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T21:12:22Z","timestamp":1711401142000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/3\/6\/1037\/6883236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,1]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2006,11,1]]},"published-print":{"date-parts":[[2006,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2006.00310.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,11]]},"published":{"date-parts":[[2006,11,1]]}}}